NDAORALCAPSULE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
7/8 — Comprehensive
COBENFY (xanomeline and trospium chloride) by Bristol Myers Squibb is cholinergic muscarinic agonists [moa]. Approved for schizophrenia. First approved in 2024.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COBENFY is an oral capsule combining xanomeline and trospium chloride, a novel fixed-dose formulation of cholinergic muscarinic agonists approved September 2024 for schizophrenia. It represents a first-in-class mechanism targeting M1 and M4 muscarinic receptors, offering a distinct pharmacological approach compared to dopamine/serotonin antagonists. This combination drug addresses an underserved patient population seeking alternative mechanisms of action in psychotic disorders.
Growth13.5 years to LOE
Early-stage growth product with nascent market penetration presents significant opportunity for brand building and team expansion across commercial and medical functions.
Mechanism of Action
Cholinergic Muscarinic Agonists
Pharmacologic Class:
Cholinergic Muscarinic Agonist
Indications (1)
Clinical Trials (2)
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
Started Jul 2026
12 enrolled
SCHIZOPHRENIA 1 (Disorder)Schizoaffecitve Disorder
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Started Feb 2026
1,500 enrolled
Schizophrenia
Worked on COBENFY at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.